BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.
Annual Meeting of Stockholders
An annual meeting (Annual Meeting) of the stockholders of Bone
Biologics Corporation, a Delaware corporation (the Company), was
held on June 5, 2017. The Company filed its definitive proxy
statement in connection with the Annual Meeting with the
Securities and Exchange Commission on May 5, 2017 (which can be
viewed at: www.sec.gov). The Companys stockholders considered the
following proposals at the Annual Meeting:
|
Proposal I: A proposal to elect Stephen LaNeve, Bruce Stroever, John Booth and Jimmy Delshad to the Companys Board of Directors; and |
||
|
Proposal II: A proposal to approve on an advisory basis the compensation of the Companys named executive officers. |
Voting Results
Proposal I: The election of each of Stephen LaNeve, Bruce
Stroever, John Booth and Jimmy Delshad was approved as follows:
33,786,265 FOR votes, 0 WITHHELD votes, and 5,042,342 NON VOTES;
Proposal II: Approval of Executive Compensation was approved with
31,844,792 FOR votes, 1,941,473 AGAINST votes and 0 ABSTAIN
votes.
About BONE BIOLOGICS CORPORATION (OTCMKTS:BBLG)
Bone Biologics Corporation is a biotechnology company. The Company is focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX combination product is an osteoinductive recombinant protein that provides target specific control over bone regeneration. The Company’s platform technology has application in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology and sports medicine. The Company’s platform technology is UCB-1, a skeletal specific growth factor used in combination with DBX, a demineralized bone matrix from Musculoskeletal Transplant Foundation (MTF). Together, with DBX, or alone, NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration. The NELL-1/DBX Fusion Device will consist of a single dose vial of NELL-1 recombinant protein freeze dried onto DBX.